Cullinan Therapeutics
Cullinan Therapeutics Inc (formerly Cullinan Oncology Inc) is an American clinical-stage biopharmaceutical enterprise specializing in the discovery, development, and commercialization of targeted oncology therapeutics and innovative immunotherapies designed to treat cancer and autoimmune diseases. The company conducts advanced clinical trials evaluating novel biopharmaceutical drug candidates, including targeted antibody-drug conjugates (ADCs) and T-cell engagers designed to maximize tumor cytotoxicity while minimizing systemic toxicity. Its core business operations encompass biopharmaceutical research, clinical trial execution, oncology drug development, and collaborative licensing partnerships. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its research activities through public equity offerings, milestone payments, and strategic biopharmaceutical collaborations. Cullinan Therapeutics holds a pioneering market position in targeted oncology and precision immunotherapy development. The company is headquartered in Cambridge, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market under the ticker CGEM.
2 of the funds FundTelligence covers report a position in Cullinan Therapeutics.
- Legal name
- Cullinan Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Cullinan Therapeutics
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.0 % (partially disclosed portfolio, June 2026)